Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The safety of daclatasvir for the treatment of hepatitis C.

Expert opinion on drug safety - 1 Jan 2015

Jafri Syed-Mohammed, Gordon Stuart C

Abstract excerpt

INTRODUCTION: The direct acting antiviral daclatasvir is an NS5A replication inhibitor active against the entire range of hepatitis C virus genotypes. It is a key step in establishing the goal of an all-oral, ribavirin-free, pan-genotypic regimen against hepatitis C. AREAS COVERED: We review current literature including published abstracts and manuscripts. Evidence was obtained through PubMed/Medline search using...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Antiviral Agents
Share to Carbamates

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C

Share to Imidazoles

Share to Pyrrolidines

Share to Valine

Share to Virus Replication

Source

Identifiers

PMID: 26571362
DOI: 10.1517/14740338.2015.1100603

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The safety of daclatasvir for the treatment of hepatitis C.PMID 26571362Read ↗

Review article: the efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection.Semantic proximity Read ↗

NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infectionSemantic proximity Read ↗

Asunaprevir for hepatitis C: a safety evaluation.Semantic proximity Read ↗

Pharmacodynamic and pharmacokinetic evaluation of the combination of daclatasvir/sofosbuvir/ribavirin in the treatment of chronic hepatitis C.Semantic proximity Read ↗

Use of Daclatasvir in HCV/HIV-Coinfected Patients in a Real-Life Setting.Semantic proximity Read ↗

Efficacy and safety of a fixed dose combination tablet of asunaprevir + beclabuvir + daclatasvir for the treatment of Hepatitis C.Semantic proximity Read ↗

Dual daclatasvir and sofosbuvir for treatment of genotype 3 chronic hepatitis C virus infection.Semantic proximity Read ↗

Daclatasvir plus sofosbuvir regimen sheds promising light on future hepatitis C virus genotype 3 therapies.Semantic proximity Read ↗

Effectiveness and safety of daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: Systematic review and meta-analysis.Semantic proximity Read ↗

Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study.Semantic proximity Read ↗

Pharmacokinetic and pharmacodynamic evaluation of daclatasvir, asunaprevir plus beclabuvir as a fixed-dose co-formulation for the treatment of hepatitis C.Semantic proximity Read ↗

Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.